Cytokine gene polymorphisms and fatigue in breast cancer survivors: Early findings

Brain, Behavior, and Immunity

Volumn 22, Issue 8, 2008, Pages 1197-1200

  Collado Hidalgo, Alicia ^a   Bower, Julienne E ^a,b,c,d   Ganz, Patricia A ^d   Irwin, Michael R ^a,c   Cole, Steve W ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA Department of Psychology   (United States)

^c UCLA Department of Psychiatry and Biobehavioral Sciences   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Cytokine gene polymorphisms; Fatigue; Proinflammatory cytokines

Indexed keywords

AROMATASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; TAMOXIFEN;

ADULT; AGED; ARTICLE; BEHAVIOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER SURVIVOR; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; COVARIANCE; CYTOKINE PRODUCTION; DEMOGRAPHY; FEMALE; GENE FREQUENCY; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM;

BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; FATIGUE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; MIDDLE AGED; ODDS RATIO; PATIENT SELECTION; POLYMORPHISM, SINGLE NUCLEOTIDE; QUESTIONNAIRES; SURVIVORS;

EID: 52949090015     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2008.05.009     Document Type: Article

References (28)

1. Andreassen C.N., Alsner J., Overgaard J., Herskind C., Haviland J., Owen R., Homewood J., Bliss J., and Yarnold J. TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother. Oncol. 75 (2005) 18-21
2. Balasubramanian S.P., Azmy I.A., Higham S.E., Wilson A.G., Cross S.S., Cox A., Brown N.J., and Reed M.W. Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review. BMC Cancer 6 (2006) 188
3. Beck A.T., Steer R.A., and Brown G.K. BDI-II Manual. second ed. (1996), The Psychological Corporation, San Antonio
4. Bower J.E., Ganz P.A., and Aziz N. Altered cortisol response to psychologic stress in breast cancer survivors with persistent fatigue. Psychosom. Med. 67 (2005) 277-280
5. Bower J.E., Ganz P.A., Aziz N., and Fahey J.L. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom. Med. 64 (2002) 604-611
6. Bower J.E., Ganz P.A., Aziz N., Fahey J.L., and Cole S.W. T-cell homeostasis in breast cancer survivors with persistent fatigue. J. Natl. Cancer Inst. 95 (2003) 1165-1168
7. Bower J.E., Ganz P.A., Aziz N., Olmstead R., Irwin M.R., and Cole S.W. Inflammatory responses to psychological stress in fatigued breast cancer survivors: relationship to glucocorticoids. Brain Behav. Immun. 21 (2007) 251-258
8. Bower J.E., Ganz P.A., Desmond K.A., Bernaards C., Rowland J.H., Meyerowitz B.E., and Belin T.R. Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer 106 (2006) 751-758
9. Bower J.E., Ganz P.A., Desmond K.A., Rowland J.H., Meyerowitz B.E., and Belin T.R. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J. Clin. Oncol. 18 (2000) 743-753
10. Bower J.E., Ganz P.A., Dickerson S.S., Petersen L., Aziz N., and Fahey J.L. Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology 30 (2005) 92-100
11. Brull D.J., Montgomery H.E., Sanders J., Dhamrait S., Luong L., Rumley A., Lowe G.D., and Humphries S.E. Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1458-1463
12. Burzotta F., Iacoviello L., Di Castelnuovo A., Glieca F., Luciani N., Zamparelli R., Schiavello R., Donati M.B., Maseri A., Possati G., and Andreotti F. Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Am. J. Cardiol. 88 (2001) 1125-1128
13. Collado-Hidalgo A., Bower J.E., Ganz P.A., Cole S.W., and Irwin M.R. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin. Cancer Res. 12 (2006) 2759-2766
14. Dantzer R., O'Connor J.C., Freund G.C., Johnson R.W., and Kelley K. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9 (2008) 46-57
15. DeMichele A., Martin A.M., Mick R., Gor P., Wray L., Klein-Cabral M., Athanasiadis G., Colligan T., Stadtmauer E., and Weber B. Interleukin-6 -174G->C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res. 63 (2003) 8051-8056
16. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S., and Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 102 (1998) 1369-1376
17. Giovine F.S., Takhsh E., Blakemore A.I.F., and Duff G.W. Single base polymorphism at -511 in the human interleukin-1{beta} gene (IL1{beta}). Hum. Mol. Genet. 1 (1992) 450
18. Hefler L.A., Grimm C., Lantzsch T., Lampe D., Leodolter S., Koelbl H., Heinze G., Reinthaller A., Tong-Cacsire D., Tempfer C., and Zeillinger R. Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women. Clin. Cancer. Res 11 (2005) 5718-5721
19. Kent S., Bluthe R.M., Kelley K.W., and Dantzer R. Sickness behavior as a new target for drug development. Trends Pharmacol. Sci. 13 (1992) 24-28
20. McCulley M.C., Day I.N., and Holmes C. Association between interleukin 1-beta promoter (-511) polymorphism and depressive symptoms in Alzheimer's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 124 (2004) 50-53
21. Olomolaiye O., Wood N.A., and Bidwell J.L. A novel NlaIII polymorphism in the human IL-6 promoter. Eur. J. Immunogenet. 25 (1998) 267
22. Reichenberg A., Yirmiya R., Schuld A., Kraus T., Haack M., Morag A., and Pollmacher T. Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry 58 (2001) 445-452
23. Schubert C., Hong S., Natarajan L., Mills P.J., and Dimsdale J.E. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav. Immun. 21 (2007) 413-427
24. Smith K.C., Bateman A.C., Fussell H.M., and Howell W.M. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur. J. Immunogenet. 31 (2004) 167-173
25. Stein K.D., Jacobsen P.B., Blanchard C.M., and Thors C. Further validation of the multidimensional fatigue symptom inventory-short form. J. Pain Symptom Manage. 27 (2004) 14-23
26. Stein K.D., Martin S.C., Hann D.M., and Jacobsen P.B. A multidimensional measure of fatigue for use with cancer patients. Cancer Pract. 6 (1998) 143-152
27. Ware Jr. J.E., and Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 30 (1992) 473-483
28. Yoshida K., Alagbe O., Wang X., Woolwine B., Thornbury M., Raison C.L., and Miller A.H. Promoter polymorphisms of the interferon-alpha receptor gene and development of interferon-induced depressive symptoms in patients with chronic hepatitis C: preliminary findings. Neuropsychobiology 52 (2005) 55-61